$CSTL insiders have traded $CSTL stock on the open market 221 times in the past 6 months. Of those trades, 0 have been purchases and 221 have been sales. Here’s a ...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Castle Biosciences Inc (Symbol: CSTL), where a total of 2,062 contracts have traded so ...

Leerink Partners analyst Puneet Souda maintained a Buy rating on Castle Biosciences (CSTL – Research Report) yesterday and set a price target of $50.00. The company’s shares closed yesterday ...

Shares of NASDAQ CSTL opened at $26.62 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78. Castle Biosciences has a 1 year low of $16. ...

Unfortunately, that's been the case for longer term Castle Biosciences, Inc. (NASDAQ:CSTL) shareholders, since the share price is down 34% in the last three years, falling well short of the market ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on CSTL stock, giving a Buy rating yesterday. Puneet Souda has given his Buy rating due to a combination of factors ...

NASDAQ:CSTL opened at $26.44 on Thursday. The stock’s 50-day simple moving average is $28.58 and its 200 day simple moving average is $28.17. The firm has a market capitalization of $740.58 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma ...